Economic evaluation of three populational screening strategies for cervical cancer in the county of Valles Occidental: CRICERVA clinical trial

被引:6
作者
Acera, Amelia [1 ,4 ]
Rodriguez, Ana [1 ]
Trapero-Bertran, Marta [2 ]
Soteras, Pilar [1 ]
Sanchez, Norman [5 ]
Bonet, Josep M. [3 ]
Manresa, Josep M. [4 ,7 ]
Hidalgo, Pablo [3 ]
Toran, Pere [4 ]
Prieto, Gemma [6 ]
机构
[1] Inst Catala Salut, ASSIR SAP Cerdanyola Ripollet, Barcelona, Spain
[2] Brunel Univ, Hlth Econ Res Grp, Uxbridge UB8 3PH, Middx, England
[3] Inst Catala Salut, SAP Cerdanyola Ripollet, Barcelona, Spain
[4] IDIAP Jordi Gol, Unitat Suport Recerca Metropolitana Nord, Sabadell, Spain
[5] Inst Catala Salut, Sistemes Informacio Sanitaria SAP Cerdanyola Ripo, Barcelona, Spain
[6] Gerencia Atenc Primaria Avila, Avila, Spain
[7] Univ Autonoma Barcelona, Dept Infermeria, Bellaterra, Spain
关键词
COST-EFFECTIVENESS; PRIMARY-CARE; HPV; BENEFITS;
D O I
10.1186/1472-6963-11-278
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: A high percentage of cervical cancer cases have not undergone cytological tests within 10 years prior to diagnosis. Different population interventions could improve coverage in the public system, although costs will also increase. The aim of this study was to compare the effectiveness and the costs of three types of population interventions to increase the number of female participants in the screening programmes for cancer of the cervix carried out by Primary Care in four basic health care areas. Methods/Design: A cost-effectiveness analysis will be performed from the perspective of public health system including women from 30 to 70 years of age (n = 20,994) with incorrect screening criteria from four basic health care areas in the Valles Occidental, Barcelona, Spain. The patients will be randomly distributed into the control group and the three intervention groups (IG1: invitation letter to participate in the screening; IG2: invitation letter and informative leaflet; IG3: invitation letter, informative leaflet and a phone call reminder) and followed for three years. Clinical effectiveness will be measured by the number of HPV, epithelial lesions and cancer of cervix cases detected. The number of deaths avoided will be secondary measures of effectiveness. The temporal horizon of the analysis will be the life expectancy of the female population in the study. Costs and effectiveness will be discounted at 3%. In addition, univariate and multivariate sensitivity analysis will be carried out. Discussion: IG3 is expected to be more cost-effective intervention than IG1 and IG2, with greater detection of HPV infections, epithelial lesions and cancer than other strategies, albeit at a greater cost.
引用
收藏
页数:7
相关论文
共 38 条
[1]   Patterns of intra-cluster correlation from primary care research to inform study design and analysis [J].
Adams, G ;
Gulliford, MC ;
Ukoumunne, OC ;
Eldridge, S ;
Chinn, S ;
Campbell, MJ .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 2004, 57 (08) :785-794
[2]  
BASTIDA JL, 2009, GACETA SANITARIA
[3]   Evaluation of cervical screening strategies with adjunct high-risk human papillomavirus testing for women with borderline or mild dyskaryosis [J].
Berkhof, J ;
de Bruijne, MC ;
Zielinski, GD ;
Bulkmans, NWJ ;
Rozendaal, L ;
Snijders, PJF ;
Verheijen, RHM ;
Meijer, CJLM .
INTERNATIONAL JOURNAL OF CANCER, 2006, 118 (07) :1759-1768
[4]  
Bosch FX, 2009, ESTUDIO AFRODITA CRI
[5]  
BOSCH FX, 2010, CASTELLSAGUE 10 PREV
[6]   An introduction to Markov modelling for economic evaluation [J].
Briggs, A ;
Sculpher, M .
PHARMACOECONOMICS, 1998, 13 (04) :397-409
[7]   The use of cervical screening history data to interpret cervical cancer incidence trends [J].
Clare, Joanne ;
Edwards, Diane ;
Bagnall, Helen ;
Pearmain, Philippa ;
Lawrence, Gill .
JOURNAL OF PUBLIC HEALTH, 2008, 30 (02) :171-177
[8]  
CORTES J, 2010, ACT PRIM FOR ESP VIR
[9]  
CUZICK J, 1999, HLTH TECHNOLOGY ASSE, V3, P95
[10]  
*DEP SAL GEN CAT, 2006, PROT ACT CRIB CANC C